"Orchiectomy" - Books

Result Filters

Results: 1 to 20 of 58 books (305 items)

<< First< Prev

Page of 3

Next >Last >>

Select item 44036681.

StatPearls [Internet].

Treasure Island (FL): StatPearls Publishing; 2024 Jan-.

Top results in this book Table of Contents

Select item 28215242.

PDQ Cancer Information Summaries [Internet].

Bethesda (MD): National Cancer Institute (US); 2002-.

Top results in this book Table of Contents

Select item 16686903.

Holland-Frei Cancer Medicine. 6th edition.

Kufe DW, Pollock RE, Weichselbaum RR, et al., editors.

Hamilton (ON): BC Decker; 2003.

Top results in this book Table of Contents

Select item 34012944.

Endotext [Internet].

Feingold KR, Anawalt B, Blackman MR, et al., editors.

South Dartmouth (MA): MDText.com, Inc.; 2000-.

Top results in this book Table of Contents

Select item 48538165.

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].

Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.

Top results in this book Table of Contents

Select item 26591826.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet].

York (UK): Centre for Reviews and Dissemination (UK); 1995-.

Top results in this book Table of Contents

Select item 55163647.

Darolutamide (Nubeqa): CADTH Reimbursement Review: Therapeutic area: Metastatic castration-sensitive prostate cancer [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Mar.

Top results in this book Table of Contents

Select item 16902488.

AHRQ Evidence Report Summaries.

Rockville (MD): Agency for Healthcare Research and Quality (US); 1998-2005.

Top results in this book Table of Contents

Select item 31813009.

Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care.

Institute of Medicine (US) Committee on Understanding and Eliminating Racial and Ethnic Disparities in Health Care; Smedley BD, Stith AY, Nelson AR, editors.

Washington (DC): National Academies Press (US); 2003.

Top results in this book Table of Contents

Select item 541219010.

Diagnostic Errors in the Emergency Department: A Systematic Review [Internet].

Newman-Toker DE, Peterson SM, Badihian S, et al.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2022 Dec. (Comparative Effectiveness Review, No. 258.)

Top results in this book Table of Contents

Select item 519578611.

Testicular cancer: Does routine screening for men aged 16 years and older lead to better treatment outcomes?: IQWiG Reports – Commission No. HT18-01 [Internet].

Cologne (Germany): Institute for Quality and Efficiency in Health Care (IQWiG); 2021 Apr 14.

Top results in this book Table of Contents

Select item 558466212.

Darolutamide (Nubeqa): CADTH Reimbursement Recommendation: Indication: For the treatment of patients with metastatic castration-sensitive prostate cancer in combination with docetaxel [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Jan.

Top results in this book Table of Contents

Select item 563487213.

Niraparib and Abiraterone Acetate (Akeega): CADTH Reimbursement Review: Therapeutic area: Metastatic castration-resistant prostate cancer [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Apr.

Top results in this book Table of Contents

Select item 273372614.

Treatments for Localized Prostate Cancer: Systematic Review to Update the 2002 U.S. Preventive Services Task Force Recommendation [Internet].

Chou R, Dana T, Bougatsos C, et al.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2011 Oct. (Evidence Syntheses, No. 91.)

Top results in this book Table of Contents

Select item 145898415.

GeneReviews® [Internet].

Adam MP, Feldman J, Mirzaa GM, et al., editors.

Seattle (WA): University of Washington, Seattle; 1993-2024.

Top results in this book Table of Contents

Select item 560050816.

Niraparib and Abiraterone Acetate (Akeega): CADTH Reimbursement Recommendation: Indication: With prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA mutated (germline and/or somatic) mCRPC, who are asymptomatic/mildly symptomatic, and in whom chemotherapy is not clinically indicated [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Feb.

Top results in this book Table of Contents

Select item 521312017.

Prostate Cancer [Internet].

Bott SRJ, Ng KL, editors.

Brisbane (AU): Exon Publications; 2021 May 27.

Top results in this book Table of Contents

Select item 242389618.

Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet].

Rockville (MD): Agency for Healthcare Research and Quality (US); 2006 Feb-.

Top results in this book Table of Contents

Select item 567652019.

Medical Terminology [Internet]. 2nd edition.

Open Resources for Nursing (Open RN); Ernstmeyer K, Christman E, editors.

Eau Claire (WI): Chippewa Valley Technical College; 2024.

Top results in this book Table of Contents

Select item 299769420.

The Guide to Clinical Preventive Services 2012: Recommendations of the U.S. Preventive Services Task Force.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Oct.

Top results in this book Table of Contents

<< First< Prev

Page of 3

Next >Last >>

Supplemental Content

Images search in Bookshelf

Figure 18. Sensitivity to Quality of Life of Orchiectomy

The cost-effectiveness of orchiectomy relative to LHRH agonists is plotted against the quality-of-life adjustment associated with orchiectomy. If the quality of life associated with orchiectomy is less than 0.88, the marginal cost-effectiveness ratio (comparing orchiectomy to LHRH agonists) is below $100,000/QALY in favor of LHRH agonists. In the base case, orchiectomy had a similar quality of life weight as DES (0.92).

Cost-Effectiveness of Androgen Suppression Therapy in Advanced Prostate Cancer.

Aronson N, Seidenfeld J, Samson DJ, et al. Relative Effectiveness and Cost-Effectiveness of Methods of Androgen Suppression in the Treatment of Advanced Prostate Cancer. Rockville (MD): Agency for Health Care Policy and Research (US); 1999 May.
Figure 19. Sensitivity Analysis on the Efficacy of Combined Androgen Blockade

Panel B  The cost effectiveness of combined androgen blockade (CAB) relative to orchiectomy at different assumptions about the efficacy of CAB. Two CAB strategies are shown: a nonsteroidal antiandrogen with an LHRH agonist (Panel A) and a nonsteroidal antiandrogen with orchiectomy (Panel B). Efficacy is presented as the relative hazard of disease progression compared to orchiectomy. The shaded areas represent the confidence intervals from the current meta-analysis and the arrows indicate the point estimates.

Cost-Effectiveness of Androgen Suppression Therapy in Advanced Prostate Cancer.

Aronson N, Seidenfeld J, Samson DJ, et al. Relative Effectiveness and Cost-Effectiveness of Methods of Androgen Suppression in the Treatment of Advanced Prostate Cancer. Rockville (MD): Agency for Health Care Policy and Research (US); 1999 May.
Figure 17. Costs and Outcomes With All Monotherapies and Combined Androgen Blockade

Assumptions about efficacy reflected the point estimates from the meta-analysis.DES$3,5674.68Orchiectomy$6,9575.10$8,092 / QALYNSAA$14,3824.61Eliminated by strict dominanceNSAA + orchiectomy$20,8575.08Eliminated by strict dominanceLHRH agonist$25,7094.89Eliminated by strict dominanceNSAA + LHRH agonist$41,4435.13$1,109,581 / QALY

Cost-Effectiveness of Androgen Suppression Therapy in Advanced Prostate Cancer.

Aronson N, Seidenfeld J, Samson DJ, et al. Relative Effectiveness and Cost-Effectiveness of Methods of Androgen Suppression in the Treatment of Advanced Prostate Cancer. Rockville (MD): Agency for Health Care Policy and Research (US); 1999 May.
Figure 21. Incorporating Biochemical Markers

Costs and effectiveness when decisions to change therapy are based on biochemical markers (PSA) as well as clinical outcomes. See text for details of assumptions.
StrategyCostEffectiveness
(QALYs)Marginal Cost-EffectivenessDES$4,8967.04Orchiectomy$8,4177.54$7,057/QALYNSAA$11,6297.49Eliminated by strict dominanceNSAA + orchiectomy$15,9197.50Eliminated by strict dominanceLHRH agonist$19,2427.54Eliminated by strict dominanceNSAA + LHRH agonist$26,7247.50Eliminated by strict dominance

Cost-Effectiveness of Androgen Suppression Therapy in Advanced Prostate Cancer.

Aronson N, Seidenfeld J, Samson DJ, et al. Relative Effectiveness and Cost-Effectiveness of Methods of Androgen Suppression in the Treatment of Advanced Prostate Cancer. Rockville (MD): Agency for Health Care Policy and Research (US); 1999 May.